BBI-5000, a new molecular entity, is a selective oral CRTH2 antagonist, having just completed the Phase 1 stage of development. Brickell intends to develop BBI-5000 as a potential once-daily oral treatment for patients with moderate to severe atopic dermatitis and androgenic alopecia (hair loss). Clinical proof of concept studies are to be performed later this year and next year.